NEW YORK (360Dx) – OptiScan Biomedical today announced its OptiScanner 6000 device for near-continuous glucose and lactate monitoring has received CE mark, allowing the firm to market it in the European Union.

The Hayward, California-based firm said it plans to launch the device later this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.